Teschke Rolf, Bahre Ruediger, Fuchs Johannes, Wolff Albrecht
Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Teaching Hospital of the Johann Wolfgang Goethe-University Frankfurt/Main, Hanau, Germany.
Menopause. 2009 Sep-Oct;16(5):956-65. doi: 10.1097/GME.0b013e31819d3904.
Black cohosh (BC), synonym for Actaea racemosa and Cimicifuga racemosa, is a herbal remedy for the treatment of menopausal symptoms. Recently, worldwide discussions have emerged as to whether its use maybe associated with the risk of rare hepatotoxicity in a few susceptible women.
We have evaluated the causal relationship in nine cases with suspected hepatotoxicity by the use of BC. The updated Council for International Organizations of Medical Sciences scale was used to quantitatively assess the causality for BC.
In eight of nine patients with liver disease, causality for BC +/- comedication was excluded (n = 4) or unlikely (n = 4). The failure to ascribe causality in these cases was mainly due to alternative diagnosis, missing temporal association and dechallenge, and presentation of low quality data. In only one case, causality was possible for a BC preparation of an unknown brand taken for 2 months with an unknown daily dose. Confounding factors in this case include symptomatic cholelithiasis and fatty liver. Comedication with synthetic drugs and herbal or other dietary supplements was reported in five of nine patients.
In nine cases of patients with liver disease, causality for BC +/- comedication was possible (n = 1), unlikely (n = 4), or excluded (n = 4). Due to this lack of significant circumstantial evidence, the present study shows little, if any, hepatotoxic risks by the use of BC in the analyzed cases.
黑升麻(BC),即总状升麻和美升麻的同义词,是一种用于治疗更年期症状的草药。最近,关于其使用是否可能与少数易感女性发生罕见肝毒性的风险相关,在全球范围内引发了讨论。
我们通过使用黑升麻评估了9例疑似肝毒性病例的因果关系。采用更新后的国际医学科学组织理事会量表对黑升麻的因果关系进行定量评估。
在9例肝病患者中,8例排除了黑升麻±合并用药的因果关系(n = 4)或可能性不大(n = 4)。这些病例未能确定因果关系主要是由于存在其他诊断、缺乏时间关联和撤药反应,以及数据质量较低。仅1例中,服用未知品牌的黑升麻制剂2个月且日剂量未知,可能存在因果关系。该病例中的混杂因素包括有症状的胆结石和脂肪肝。9例患者中有5例报告了与合成药物以及草药或其他膳食补充剂合并用药的情况。
在9例肝病患者中,黑升麻±合并用药的因果关系可能存在(n = 1)、可能性不大(n = 4)或可排除(n = 4)。由于缺乏重要的旁证,本研究表明,在所分析的病例中,使用黑升麻几乎不存在肝毒性风险(即便有也微乎其微)。